logo

Video encyclopedia

Liraglutide

1:51

Liraglutide and Cardiovascular Outcomes

11:23

Victoza

4:19

AHA 2015 | Liraglutide for High-Risk Heart Failure Patients

3:00

Glucagon Like Peptide 1: Incretin Exenatide/ Liraglutide Pharmacology: Newer antidiabetic Medication

8:07

Victoza Side Effects, Weight loss, Thyroid Cancer Warning

Liraglutide (NN2211) is a derivative of human incretin glucagon-like peptide-1 (GLP-1) that is used as a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing a separate strength in the U.S. and E.U. under the brand name Saxenda as a treatment for adults who are obese or overweight with at least one weight-related comorbid condition.
Explore contextually related video stories in a new eye-catching way. Try Combster now!